Lymphatic system

Life-Saving Innovations in Cancer-Fighting Stem Cell Transplants and Pioneering Research in HIV, Autism and Cerebral Palsy to be Featured at World Cord Blood Day 2022

Retrieved on: 
Wednesday, September 14, 2022
Partner, AABB, Temperature, Laboratory, Child, Transplant, Eventbrite, Nursing, FACT, Accreditation, HIV, LinkedIn, Kuehne + Nagel, Umbilical cord, Thalassemia, Facebook, Leukemia, Student, Cell, Bone marrow, NMDP, Foundation, Method, Lymphatic system, World Marrow Donor Association, Research, Parent, Association, Hospital, Education, Placenta, Lymphoma, Waste, WCBD, Cerebral palsy, Autism, Medical device, Pharmaceutical industry, Birth control, Blood

TUCSON, Ariz., Sept. 14, 2022 /PRNewswire/ -- We are pleased to announce World Cord Blood Day 2022 (WCBD 2022) will take place on November 15th, featuring a free online medical conference and educational events worldwide. This year's official online conference will highlight innovations in cancer-fighting stem cell transplants using cord blood, as well as ground-breaking cord blood research and novel cell therapies in the potential treatment of HIV, autism, cerebral palsy and more.

Key Points: 
  • Learn how cord blood is used to treat 80+ life-threatening diseases including many blood cancers and holds tremendous potential in the treatment of HIV, autism and cerebral palsy.
  • TUCSON, Ariz., Sept. 14, 2022 /PRNewswire/ -- We are pleased to announce World Cord Blood Day 2022 (WCBD 2022) will take place on November 15th, featuring a free online medical conference and educational events worldwide.
  • This year's official online conference will highlight innovations in cancer-fighting stem cell transplants using cord blood, as well as ground-breaking cord blood research and novel cell therapies in the potential treatment of HIV, autism, cerebral palsy and more.
  • Cord blood is the blood left in the umbilical cord and placenta following the birth of a child.

Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference

Retrieved on: 
Wednesday, September 14, 2022
Exchange, Lymphoid leukemia, Risk, AML, Company, List of life sciences, Hematology, Acute myeloid leukemia, Toxic epidermal necrolysis, Lymphatic system, MDS, Patient, Pharmaceutical industry

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.

Key Points: 
  • Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.
  • The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
  • Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release.
  • Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022

Retrieved on: 
Wednesday, September 14, 2022
European Medicines Agency, Holm–Bonferroni method, Trial of the century, PRIME, Risk, FDA, Neoplasm, GVHD, Company, Private Securities Litigation Reform Act, Hodgkin lymphoma, Therapy, Patient, Baylor University, Technology, Cell, Graft-versus-host disease, Lymphatic system, Hematological Cancer Research Investment and Education Act, Infrastructure as code, TT11, GLOBE, Epstein–Barr virus, Marketing, Immune system, Cancer, Toxicity, Baylor College of Medicine, Pharmaceutical industry

SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that TT11X, the companys allogeneic off-the-shelf CD30.CAR EBVST cell therapy, has been recognized in the Most Promising Off-the-Shelf Therapies category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022 .

Key Points: 
  • SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that TT11X, the companys allogeneic off-the-shelf CD30.CAR EBVST cell therapy, has been recognized in the Most Promising Off-the-Shelf Therapies category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022 .
  • The ACGTEA 2022 Awards were held in conjunction with the 6th Cell & Gene Therapy World Asia 2022.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.
  • Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility.

Be The Match and William G. Pomeroy Foundation® Announce $500k Gift and Matching Campaign

Retrieved on: 
Tuesday, September 13, 2022
University, Probability, Transplant, Trustee, Life, Historically black colleges and universities, Patient, National Marrow Donor Program, Leukemia, Student, Lymphatic system, Awareness, Education, Color, Pharmaceutical industry, Medical device, Dentistry, Match

MINNEAPOLIS, Sept. 13, 2022 /PRNewswire/ -- In support of enhanced accessibility to life-saving stem cell transplants through the Be The Match® Registry, the William G. Pomeroy Foundation has made a $500,000 grant to Be The Match that will further the organization's partnerships at historically Black colleges and universities (HBCUs).

Key Points: 
  • In addition, the Pomeroy Foundation donation sponsors a gift matching campaign that will help to diversify the donor registry.
  • Donations to Be The Match throughout the month of September will be matched dollar for dollar, up to $500,000.
  • "Patients are most likely to match a donor of their own ethnic background," said Bill Pomeroy, Founder and Trustee of the Pomeroy Foundation.
  • To double your donation to Be The Match during this month's matching gift campaign and to learn more about diversifying the Be The Match Registry, visit: bethematch.org .

TC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune®

Retrieved on: 
Tuesday, September 13, 2022
Freeze thaw resistance, Time, Quality control, Efficiency, Canadian Aviation Regulations, Holding, New product development, Company, Kobel, Achievement, TC, Patient, Cancer, Thought, Production, CEO, Acute myeloid leukemia, MHRA, NASDAQ, PLC, Lymphatic system, AML, Multimedia, View, CAR, Pharmaceutical industry, Medical imaging, TCB

Additionally, TC BioPharm's in-house quality control department will continue to gather data in order to extend the shelf-life of OmnImmune.

Key Points: 
  • Additionally, TC BioPharm's in-house quality control department will continue to gather data in order to extend the shelf-life of OmnImmune.
  • "The approval received from the MHRA for our frozen product is another very important piece of a complex jigsaw.
  • It is indeed a further step towards the achievement of a platform to deliver truly off-the-shelf products in the cell therapy space.
  • We are extremely pleased to receive MHRA approval for our Freeze/Thawed product, OmnImmune, the first freeze/thawed gamma delta product in clinical trials.

Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal

Retrieved on: 
Tuesday, September 13, 2022
Cancer, GLOBE, List of Nature Research journals, Patient, Lymphatic system, Immunotherapy, NASDAQ, Pharmaceutical industry

At the time of data cutoff, while median overall survival had not been reached, the mean overall survival was 9.1 months.

Key Points: 
  • At the time of data cutoff, while median overall survival had not been reached, the mean overall survival was 9.1 months.
  • The most common grade 3/4 adverse events were cytopenias (thrombocytopenia (75%) and neutropenia (57%)), which is consistent with previous studies.
  • The WM cohort will enroll up to 50 patients to evaluate the efficacy and safety of iopofosine for marketing approval.
  • The company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.

Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.

Retrieved on: 
Tuesday, September 13, 2022
Risk, VP, TSX, Director, Lymphatic system, Genome, Company, Hematology, Industry, Massachusetts General Hospital, MDS, Patient, Exchange, CEO, Bristol Myers Squibb, Acute myeloid leukemia, Toxic epidermal necrolysis, CSO, APS, Bioinvent, NASDAQ, Princeton University, Harvard Medical School, SAN, Board, Biotechnology, AML, GLOBE, GPC Biotech, Pharmaceutical industry, Management

Aptoses Board of Directors now includes seven members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development.

Key Points: 
  • Aptoses Board of Directors now includes seven members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development.
  • He is Chairman of the Board of Directors for Oxford Biotherapeutics (U.K.) and serves in board positions for Aprea (Sweden), Oncolytics (Canada), Vaccibody (Norway), and BioInvent (Sweden).
  • We very much look forward to working with him and having him lend his insight and vast global biopharmaceutical experience to Aptose as a member of our Board of Directors.
  • I am excited to join the Aptose Board at such a pivotal time in the companys evolution, said Dr. Seizinger.

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Retrieved on: 
Tuesday, September 13, 2022
Safety, COVID-19, EDGAR, FDA, Food, Company, Population, Form 10-K, Degenerative disease, Private Securities Litigation Reform Act, News, Therapy, Forward-looking statement, Neoplasm, Program, Patient, TCR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Technology, ARTEMIS, Progression-free survival, Nasdaq, Lymphatic system, Marker, Antigen, Toxic epidermal necrolysis, Research, AML, MRD, GLOBE, SEC, PR, Disease, Pharmaceutical industry, Vaccine

The FDA grant will support the Companys treatment arm evaluating MT-401 in patients with post-transplant AML with minimal residual disease.

Key Points: 
  • The FDA grant will support the Companys treatment arm evaluating MT-401 in patients with post-transplant AML with minimal residual disease.
  • MT-401 was granted Orphan Drug Designation for the treatment of patients with AML following allogeneic stem cell transplant in 2020.
  • This grant will enable us to further advance our development of MT-401 to potentially treat a patient population where no treatments have been approved.
  • The multicenter Phase 2 AML study is evaluating the clinical efficacy of MT-401 in patients with AML following an allogeneic stem-cell transplant in both the adjuvant and active disease setting.

NCCN's New Patient Guidelines for Marginal Zone Lymphoma Help Patients and Caregivers Better Understand a Rare Form of Blood Cancer

Retrieved on: 
Monday, September 12, 2022
Lymph, Breast, Policy, Blood, Infection, Patient, National Comprehensive Cancer Network, Strathcona County, Research, CAR, COVID-19, Lymphatic system, Incidence, Person, Bone marrow, Doctor of Philosophy, Journal of the National Comprehensive Cancer Network, Skin, Spleen, NCCN, Stomach, Decision-making, Robert H. Lurie Comprehensive Cancer Center, Lymphoma, Health, Memorial Sloan Kettering Cancer Center, Feinberg School of Medicine, Twitter, Prostate, Immunotherapy, Cancer, Pathology, Diagnosis, PMID, Caregiver, Lung, Awareness, Education, Toxicity, Vaccine, Pharmaceutical industry, Medical device, Medicine, Amazon, MD, B-cell lymphoma

PLYMOUTH MEETING, Pa., Sept. 12, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Marginal Zone Lymphoma. A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin lymphoma cases1.

Key Points: 
  • A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin lymphoma cases1.
  • The patient guidelines for Marginal Zone Lymphoma guidelines are the latest in NCCN's library of NCCN Guidelines for Patients , published through funding from the NCCN Foundation and available online free of charge.
  • NCCN Guidelines for Patients are available for free online at NCCN.org/patientguidelines and via the NCCN Patient Guides for Cancer App .
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

NCCN's New Patient Guidelines for Marginal Zone Lymphoma Help Patients and Caregivers Better Understand a Rare Form of Blood Cancer

Retrieved on: 
Monday, September 12, 2022
Lymph, Breast, Policy, Blood, Infection, Patient, National Comprehensive Cancer Network, Strathcona County, Research, CAR, COVID-19, Lymphatic system, Incidence, Person, Bone marrow, Doctor of Philosophy, Journal of the National Comprehensive Cancer Network, Skin, Spleen, NCCN, Stomach, Decision-making, Robert H. Lurie Comprehensive Cancer Center, Lymphoma, Health, Memorial Sloan Kettering Cancer Center, Feinberg School of Medicine, Twitter, Prostate, Immunotherapy, Cancer, Pathology, Diagnosis, PMID, Caregiver, Lung, Awareness, Education, Toxicity, Vaccine, Pharmaceutical industry, Medical device, Medicine, Amazon, MD, B-cell lymphoma

PLYMOUTH MEETING, Pa., Sept. 12, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Marginal Zone Lymphoma. A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin lymphoma cases1.

Key Points: 
  • A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin lymphoma cases1.
  • The patient guidelines for Marginal Zone Lymphoma guidelines are the latest in NCCN's library of NCCN Guidelines for Patients , published through funding from the NCCN Foundation and available online free of charge.
  • NCCN Guidelines for Patients are available for free online at NCCN.org/patientguidelines and via the NCCN Patient Guides for Cancer App .
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .